CareLit · DOI-Nachweis · Pneumologie
Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) beyond week 52: Data from the Phase II TOMORROW trial
DOI 10.1055/s-0036-1571999
Bibliografische Angaben
Nachweis in CareLit
Autor:innenU Costabel, M Selman, Z Xu, T Kimura, S Stowasser, C Hallmann, L Richeldi
ZeitschriftPneumologie
Ausgabe02/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Background: Period 1 of the TOMORROW trial was a phase II, randomised, placebo-controlled trial of four doses of nintedanib (50 mg qd, 50 mg bid, 100 mg bid, 150 mg bid) in patients with IPF over 52 weeks. After completing period 1, patients had the option to continue treatment in a further blinded treatment phase (period 2). Methods: In period 2, patients receiving nintedanib in period 1 continued their dose, and p…
Zitieren
Zitierempfehlung
U Costabel, M Selman, Z Xu, T Kimura, S Stowasser, C Hallmann, L Richeldi (2016) Efficacy and safety of nintedanib in patients with idiopathic pulmonary fibrosis (IPF) beyond week 52: Data from the Phase II TOMORROW trial. Pneumologie (02). https://doi.org/10.1055/s-0036-1571999
Mit CareLit weiterarbeiten